

Table S1: Distribution of samples

| | Arrays | Biopsy | | | Surgery | | | Relapse | | | |
|--------|--------|-----------|----|----|---------|-------|----|---------|--------|---------|---|
| | | Ov/FT | Om | P | Others | Ov/FT | Om | P | Others | Ascites | |
| 1 | 16/20 | | | 10 | | | 6 | | | | |
| 2 | 3/5 | | | | | | | | 3 | | |
| 3 | 18/20 | | | | | | 4 | | 14 | | |
| 4 | 1/3 | | | 1 | | | | | | | |
| 5 | 29/29 | | 2 | | | 1 | 20 | | 5 | 1 | |
| 6 | 8/8 | | 1 | | | | 7 | | | | |
| 7 | 7/8 | | | 2 | | 1 | 4 | | | | |
| 8 | 11/11 | 1 | 1 | | | | 8 | | | 1 | |
| 9 | 15/16 | | 3 | | | | 5 | 1 | 6 | | |
| 10 | 9/11 | | | 1 | | | 8 | | | | |
| 11 | 7/17 | 1 | 4 | | 1 | 1 | | | | | |
| 12 | 1/4 | | 1 | | | | | | | | |
| 13 | 3/3 | | 1 | | | | | | 2 | | |
| 14 | 3/4 | | | | 1 | 1 | 1 | | | | |
| 15 | 3/5 | | | | | 3 | | | | | |
| 16 | 1/3 | | 1 | | | | | | | | |
| 17 | 3/4 | | | | | 1 | 2 | | | | |
| total# | 17 | 138 / 171 | 2 | 14 | 14 | 11 | 8 | 75 | 1 | 11 | 2 |

Table 1: **Distribution of samples from the OV03/OV04 clinical studies across sites and time of sampling.** Table shows eligible patients recruited to the OV03/OV04 clinical studies and the number of samples available for genomic studies collected from various metastatic sites and at biopsy, interval debulking surgery and at relapse. Ov: Ovary; FT: Fallopian tube; Om: Omentum; P: Peritoneum.